Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

Research output: Contribution to journalArticle

176 Citations (Scopus)

Abstract

Patients with advanced cancers - particularly breast and prostate cancers - are at high risk for bone metastasis, leading to accelerated bone resorption and clinically significant skeletal morbidity. Bisphosphonates are effective inhibitors of bone resorption and reduce the risk of skeletal complications in patients with bone metastases. The standard routes of administration for bisphosphonates used in clinical practice are either oral or i.v. infusion. Oral administration of bisphosphonates is complicated by poor bioavailability (generally

Original languageEnglish
Pages (from-to)28-37
Number of pages10
JournalThe oncologist
Volume9
Issue numberSUPPL. 4
DOIs
Publication statusPublished - 2004

Fingerprint

Diphosphonates
Safety
Prostatic Neoplasms
Bone Density Conservation Agents
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Bone Resorption
Biological Availability
Oral Administration
Morbidity

Keywords

  • Advanced cancer
  • Bisphosphonates
  • Bone metastases
  • Zoledronic acid

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. / Conte, PierFranco; Guarneri, Valentina.

In: The oncologist, Vol. 9, No. SUPPL. 4, 2004, p. 28-37.

Research output: Contribution to journalArticle

@article{8f02e456aea042e7b5ce5db82a7b850a,
title = "Safety of intravenous and oral bisphosphonates and compliance with dosing regimens",
abstract = "Patients with advanced cancers - particularly breast and prostate cancers - are at high risk for bone metastasis, leading to accelerated bone resorption and clinically significant skeletal morbidity. Bisphosphonates are effective inhibitors of bone resorption and reduce the risk of skeletal complications in patients with bone metastases. The standard routes of administration for bisphosphonates used in clinical practice are either oral or i.v. infusion. Oral administration of bisphosphonates is complicated by poor bioavailability (generally",
keywords = "Advanced cancer, Bisphosphonates, Bone metastases, Zoledronic acid",
author = "PierFranco Conte and Valentina Guarneri",
year = "2004",
doi = "10.1634/theoncologist.9-90004-28",
language = "English",
volume = "9",
pages = "28--37",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

AU - Conte, PierFranco

AU - Guarneri, Valentina

PY - 2004

Y1 - 2004

N2 - Patients with advanced cancers - particularly breast and prostate cancers - are at high risk for bone metastasis, leading to accelerated bone resorption and clinically significant skeletal morbidity. Bisphosphonates are effective inhibitors of bone resorption and reduce the risk of skeletal complications in patients with bone metastases. The standard routes of administration for bisphosphonates used in clinical practice are either oral or i.v. infusion. Oral administration of bisphosphonates is complicated by poor bioavailability (generally

AB - Patients with advanced cancers - particularly breast and prostate cancers - are at high risk for bone metastasis, leading to accelerated bone resorption and clinically significant skeletal morbidity. Bisphosphonates are effective inhibitors of bone resorption and reduce the risk of skeletal complications in patients with bone metastases. The standard routes of administration for bisphosphonates used in clinical practice are either oral or i.v. infusion. Oral administration of bisphosphonates is complicated by poor bioavailability (generally

KW - Advanced cancer

KW - Bisphosphonates

KW - Bone metastases

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=5444243800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444243800&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.9-90004-28

DO - 10.1634/theoncologist.9-90004-28

M3 - Article

C2 - 15459427

AN - SCOPUS:5444243800

VL - 9

SP - 28

EP - 37

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - SUPPL. 4

ER -